Caribou Biosciences announces results from CaMMouflage Phase 1 trial

Caribou Biosciences (CRBU) announced its first clinical data from dose escalation in the ongoing CaMMouflage phase 1 trial evaluating CB-011, an off-the-shelf anti-BCMA CAR-T cell therapy, in relapsed or refractory multiple myeloma, highlighting CB-011 as a potentially best-in-class allogeneic CAR-T cell therapy for this patient population. The Company is advancing the program into dose expansion, which it expects to initiate by the end of this year, and the Company plans to share dose expansion data in 2026. The median follow-up for patients dosed with the RDE was 8.3 months, and the longest responding patient is in a stringent complete response at 15 months post-infusion. As of the September 24, 2025, data cutoff date, the results for the 12-patient, BCMA-naive cohort treated with the RDE were as follows: 92% overall response rate; 75% greater than or equal tocomplete response rate; 91% achieved minimal residual disease negativity; 7 of 12 patients remained on study as of the data cutoff date in greater than or equal tovery good partial response 6 months or longer following receipt of a single dose of CB-011